Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
24 Maggio 2024 - 10:30PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair
of the Board of Recursion, effective at the end of this term, as
Martin Chavez exits after more than four years of leadership.
“I’m excited to bring my clinical and scientific expertise to
support Recursion’s growth as Chair of the Board,” said Dr.
Hershberg. “In my opinion, the intersection of scientific rigor and
technology to drive novel programs is the future of drug discovery
and I believe Recursion will be a leader in this emerging
space.”
Dr. Hershberg has served as a member of Recursion’s Board since
May 2020. He is the Chief Executive Officer, President, and Chair
of the Board of HilleVax, Inc., a biopharmaceutical company focused
on the development and commercialization of novel vaccine
candidates. Since 2020, he has also been a Venture Partner at
Frazier Healthcare Partners. Dr. Hershberg formerly served as the
executive vice president and head of business development and
global alliances at Celgene (acquired by Bristol-Myers Squibb in
2019). He joined Celgene in 2014 and was employed in positions of
ascending responsibility, including his role as Chief Scientific
Officer from January 2016 to March 2020. Before Celgene, he served
several roles at VentiRx Pharmaceuticals, a clinical-stage
biopharmaceutical company which he co-founded in 2006 and was Chief
Executive Officer from September 2012 until the company’s
acquisition by Celgene in February 2017. Dr Hershberg is a member
of the board of directors of Adaptive Biotechnologies, Scientific
Advisory Board of Danaher Corporation, Dragonfly Therapeutics,
Skyhawk Therapeutics, and the Institute for Protein Design at the
University of Washington. Rob holds a Ph.D. in biology from the
University of California, San Diego’s Affiliated Ph.D. program with
the Salk Institute and an M.D. and a B.A. from the University of
California, Los Angeles.
“As we continue to build our pipeline and clinical trials, I’m
excited to welcome Robert into this role with his decades of drug
discovery and commercialization experience.” said Chris Gibson, CEO
and Co-founder of Recursion. “I also want to thank Martin for his
incredible guidance and mentorship, both to the company and to me,
as we have matured and grown into the TechBio leader we are today,
and I look forward to our paths crossing frequently in the
future.”
"TechBio will revolutionize the biopharma industry and Recursion
continues to lead the revolution,” said R. Martin Chavez. “Being
the Chair of the Board for Recursion has been an incredible
experience, and I am delighted that Rob will lead the Board through
this next chapter as multiple clinical readouts arrive.”
About RecursionRecursion (NASDAQ: RXRX) is a
clinical stage TechBio company leading the space by decoding
biology to industrialize drug discovery. Enabling its mission is
the Recursion OS, a platform built across diverse technologies that
continuously expands one of the world’s largest proprietary
biological and chemical datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, and chemistry to advance the future of
medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
Media ContactMedia@Recursion.com
Investor ContactInvestor@Recursion.com
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, those
regarding Recursion’s growth; Recursion’s leadership of the TechBio
space; early and late stage discovery, preclinical, and clinical
programs; licenses and collaborations; prospective products and
their potential future indications and market opportunities;
Recursion OS and other technologies; business and financial plans
and performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as “plan,” “will,” “expect,” “anticipate,”
“intend,” “believe,” “potential,” “continue,” and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; inflation and other macroeconomic issues; and other
risks and uncertainties such as those described under the heading
“Risk Factors” in our filings with the U.S. Securities and Exchange
Commission, including our most recent Quarterly Report on Form 10-Q
and our Annual Report on Form 10-K for the Fiscal Year Ended
December 31, 2023. All forward-looking statements are based on
management’s current estimates, projections, and assumptions, and
Recursion undertakes no obligation to correct or update any such
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law.
Ryan Kelly
Recursion Pharmaceuticals
610-442-1896
ryan.kelly@recursionpharma.com
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Set 2023 a Set 2024